NetGenics Licenses DiscoveryCenter to Avalon Pharmaceuticals | GenomeWeb

NEW YORK, Oct. 22 – NetGenics has licensed its DiscoveryCenter integration software product to Avalon Pharmaceuticals to help it integrate its genomic, cytogenetic, and chemistry data, Avalon said on Monday.

“We are building the next generation genomics drug discovery platform,'' Ken Carter PhD, Avalon's president and CEO, said in a statement. “DiscoveryCenter will play a key role in our success, as it provides us with the ability to integrate and analyze huge amounts of data, and NetGenics will provide a fundamental building block to our cutting edge bioinformatics platform.''

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.